AB
ACTU

Amalgamated Bank’s Actuate Therapeutics ACTU Stock Holding History

Amalgamated Bank’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-298
Closed -$2K – 2881
2025
Q4 		$2K Buy
298
+97
+48% +$666 ﹤0.01% 2928
2025
Q3 		$1K Hold
201
– – ﹤0.01% 2984
2025
Q2 		$1K Buy
+201
New +$1.76K ﹤0.01% 3006

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Bank's ACTU Position: Q1 2026 in Review

Amalgamated Bank sold out of Actuate Therapeutics (ACTU) in Q1 2026, closing a stake of 298 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in ACTU in Q2 2025 and held it in 3 quarters. The position peaked at $2K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Amalgamated Bank reported no remaining Actuate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 298 Actuate Therapeutics shares in Q1 2026, an estimated $2K.
  • Amalgamated Bank first reported a position in Actuate Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Actuate Therapeutics position peaked at $2K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.